<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742117</url>
  </required_header>
  <id_info>
    <org_study_id>11-006837</org_study_id>
    <secondary_id>5U01HL128606</secondary_id>
    <secondary_id>3U01HL128606-03S1</secondary_id>
    <nct_id>NCT01742117</nct_id>
  </id_info>
  <brief_title>Tailored Antiplatelet Therapy Following PCI</brief_title>
  <acronym>TAILOR-PCI</acronym>
  <official_title>Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spartan Bioscience Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Applied Health Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration&#xD;
      (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary&#xD;
      stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some&#xD;
      studies have suggested that patients who have a certain genetic liver enzyme abnormality&#xD;
      (known as cytochrome P450 2C19 [CYP2C19] *2 or *3 allele) may have a reduced ability to&#xD;
      activate clopidogrel, and therefore may have a lowered response to clopidogrel. It is thought&#xD;
      that perhaps people who have a coronary stent procedure may have this genetic liver enzyme&#xD;
      abnormality. There is a research genetic test available to determine whether or not someone&#xD;
      has this genetic liver enzyme abnormality. Ticagrelor, is a newer anti-platelet drug that is&#xD;
      not dependent on the CYP2C19 liver enzyme for its activation and hence in poor clopidogrel&#xD;
      metabolizers, alternative drugs like Ticagrelor have been recommended for use as an&#xD;
      anti-platelet agent after PCI. The purpose of this study is to determine if genetic testing&#xD;
      can identify the best anti-platelet therapy, for patients who undergo a coronary stent&#xD;
      placement and do not activate clopidogrel very well.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAILOR-PCI is a multi-site, open label, prospective, randomized trial testing the hypothesis&#xD;
      that after percutaneous coronary intervention (PCI), using a genotyping strategy ticagrelor&#xD;
      90 mg twice per day is superior to clopidogrel 75 mg per day in reducing a composite endpoint&#xD;
      of major adverse cardiovascular events (MACE), i.e., non-fatal myocardial infarction,&#xD;
      non-fatal stroke, severe recurrent ischemia, cardiovascular (CV) death, and stent thrombosis&#xD;
      (primary endpoints) in CYP2C19 reduced function allele patients. Patients who undergo PCI&#xD;
      will be randomized to a conventional therapy arm (i.e., to receive clopidogrel 75 mg once&#xD;
      daily without prospective genotyping guidance) versus a prospective CYP2C19 genotype-based&#xD;
      anti-platelet therapy approach (ticagrelor 90 mg bid in CYP2C19 *2 or *3 reduced function&#xD;
      allele patients, clopidogrel 75 mg once daily in non-*2 or -*3 CYP2C19 patients). Buccal&#xD;
      swabs will be obtained for those subjects randomized to the prospective genotyping arm. All&#xD;
      subjects will have a blood sample drawn for DNA analysis but genotyping using these DNA&#xD;
      samples will be performed only after completion of the duration of anti-platelet therapy&#xD;
      (i.e., after one year). The primary endpoints will be assessed prospectively and will be&#xD;
      compared between the conventional arm and the prospective genotyping arm among those&#xD;
      identified as reduced function CYP2C19 allele carriers according to the 1-year genotype&#xD;
      results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">October 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.</measure>
    <time_frame>1 year after percutaneous coronary intervention (PCI)</time_frame>
    <description>Number of subjects who experienced major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis in subjects identified as CPY2C19 LOF carriers by TaqMan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of the a Major Adverse Cardiovascular Event</measure>
    <time_frame>Approximately 3 years after percutaneous coronary intervention (PCI)</time_frame>
    <description>Number of subjects to experience a major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.</measure>
    <time_frame>1 year after percutaneous coronary intervention (PCI)</time_frame>
    <description>Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding in subjects identified as CYP2C19 LOF carriers by TaqMan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis in Myocardial Infarction Major or Minor Bleeding</measure>
    <time_frame>Approximately 3 years after percutaneous coronary intervention (PCI)</time_frame>
    <description>Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5276</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Stenosis</condition>
  <arm_group>
    <arm_group_label>Genotype-Guided Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>One 75 mg tablet per day by mouth for one year</description>
    <arm_group_label>Conventional Therapy</arm_group_label>
    <arm_group_label>Genotype-Guided Therapy</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>One 90 mg tablet twice per day by mouth for one year</description>
    <arm_group_label>Genotype-Guided Therapy</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          -  Patient &gt;18 years of age&#xD;
&#xD;
          -  Patient presents with acute coronary syndrome (ACS) or stable coronary artery disease&#xD;
             (CAD)&#xD;
&#xD;
          -  Patient is eligible for PCI&#xD;
&#xD;
          -  Patient is willing and able to provide informed written consent&#xD;
&#xD;
        5.3 Exclusion&#xD;
&#xD;
          -  Patient not able to receive 12 months of dual anti-platelet therapy&#xD;
&#xD;
          -  Failure of index PCI&#xD;
&#xD;
          -  Patient or physician refusal to enroll in the study&#xD;
&#xD;
          -  Patient with known CYP2C19 genotype prior to randomization&#xD;
&#xD;
          -  Planned revascularization of any vessel within 30 days post-index procedure and/or of&#xD;
             the target vessel(s) within 12 months post-procedure&#xD;
&#xD;
          -  Anticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow up&#xD;
             period, example for elective surgery&#xD;
&#xD;
          -  Serum creatinine &gt;2.5 mg/dL within 7 days of index procedure&#xD;
&#xD;
          -  Platelet count &lt;80,000 or &gt;700,000 cells/mm3, or white blood cell count &lt;3,000&#xD;
             cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index&#xD;
             procedure.&#xD;
&#xD;
          -  History of intracranial hemorrhage&#xD;
&#xD;
          -  Known hypersensitivity to clopidogrel or ticagrelor or any of its components&#xD;
&#xD;
          -  Patient is participating in an investigational drug or device clinical trial that has&#xD;
             not reached its primary endpoint&#xD;
&#xD;
          -  Patient previously enrolled in this study&#xD;
&#xD;
          -  Patient is pregnant, lactating, or planning to become pregnant within 12 months&#xD;
&#xD;
          -  Patient has received an organ transplant or is on a waiting list for an organ&#xD;
             transplant&#xD;
&#xD;
          -  Patient is receiving or scheduled to receive chemotherapy within 30 days before or&#xD;
             after the procedure&#xD;
&#xD;
          -  Patient is receiving immunosuppressive therapy or has known immunosuppressive or&#xD;
             autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous,&#xD;
             etc.)&#xD;
&#xD;
          -  Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist,&#xD;
             direct thrombin inhibitor, Factor Xa inhibitor)&#xD;
&#xD;
          -  Concomitant use of simvastatin/lovastatin &gt; 40 mg qd&#xD;
&#xD;
          -  Concomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir,&#xD;
             itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir,&#xD;
             telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone,&#xD;
             phenobarbital, phenytoin, rifampin, and rifapentine)&#xD;
&#xD;
          -  Non-cardiac condition limiting life expectancy to less than one year, per physician&#xD;
             judgment (e.g. cancer)&#xD;
&#xD;
          -  Known history of severe hepatic impairment&#xD;
&#xD;
          -  Patient has a history of bleeding diathesis or coagulopathy or will refuse blood&#xD;
             transfusions&#xD;
&#xD;
          -  Patient has an active pathological bleeding, such as active gastrointestinal (GI)&#xD;
             bleeding&#xD;
&#xD;
          -  Inability to take aspirin at a dosage of 100 mg or less&#xD;
&#xD;
          -  Current substance abuse (e.g., alcohol, cocaine, heroin, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naveen Pereira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael E Farkouh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kent R Bailey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp HealthCare</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuckerberg San Francisco General</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCH Heart Institute</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Healthcare</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essentia Institute of Rural Health</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Feinstein Institute for Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of Schenectady</name>
      <address>
        <city>Schenectady</city>
        <state>New York</state>
        <zip>12309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHS, Eau Claire</name>
      <address>
        <city>Eau Claire</city>
        <state>Wisconsin</state>
        <zip>54702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital, UBC Division of Cardiology</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5N 3W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humber River Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Services Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital - UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regina General Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchawan</state>
        <zip>S4P 0W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konyang University College of Medicine</name>
      <address>
        <city>Daejeon</city>
        <zip>302-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Especialidades, Centro Medico Nacional 'La Raza'</name>
      <address>
        <city>Mexico City</city>
        <zip>02990</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital REgional No. 1</name>
      <address>
        <city>Mexico City</city>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cardiologia, Centro Medico Nacional Siglo XXI</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M, Bae JH, Jeong MH, Chavez I, Gordon P, Abbott JD, Cagin C, Baudhuin L, Fu YP, Goodman SG, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay JF, Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K, Rihal C. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA. 2020 Aug 25;324(8):761-771. doi: 10.1001/jama.2020.12443.</citation>
    <PMID>32840598</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <results_first_submitted>October 11, 2021</results_first_submitted>
  <results_first_submitted_qc>October 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2021</results_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Naveen L. Pereira</investigator_full_name>
    <investigator_title>Professor of Medicine, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT01742117/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Genotype-Guided Therapy</title>
          <description>Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year&#xD;
Ticagrelor: One 90 mg tablet twice per day by mouth for one year</description>
        </group>
        <group group_id="P2">
          <title>Conventional Therapy</title>
          <description>Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2641"/>
                <participants group_id="P2" count="2635"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2641"/>
                <participants group_id="P2" count="2635"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Genotype-Guided Therapy</title>
          <description>Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year&#xD;
Ticagrelor: One 90 mg tablet twice per day by mouth for one year</description>
        </group>
        <group group_id="B2">
          <title>Conventional Therapy</title>
          <description>Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2641"/>
            <count group_id="B2" value="2635"/>
            <count group_id="B3" value="5276"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="26" upper_limit="95"/>
                    <measurement group_id="B2" value="62" lower_limit="21" upper_limit="93"/>
                    <measurement group_id="B3" value="62" lower_limit="21" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="648"/>
                    <measurement group_id="B2" value="645"/>
                    <measurement group_id="B3" value="1293"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1993"/>
                    <measurement group_id="B2" value="1990"/>
                    <measurement group_id="B3" value="3983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1750"/>
                    <measurement group_id="B2" value="1754"/>
                    <measurement group_id="B3" value="3504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="595"/>
                    <measurement group_id="B2" value="592"/>
                    <measurement group_id="B3" value="1187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latinx ethnicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="577"/>
                    <measurement group_id="B2" value="580"/>
                    <measurement group_id="B3" value="1157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="654"/>
                    <measurement group_id="B2" value="650"/>
                    <measurement group_id="B3" value="1304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1359"/>
                    <measurement group_id="B2" value="1358"/>
                    <measurement group_id="B3" value="2717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.</title>
        <description>Number of subjects who experienced major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis in subjects identified as CPY2C19 LOF carriers by TaqMan.</description>
        <time_frame>1 year after percutaneous coronary intervention (PCI)</time_frame>
        <population>For 1 year endpoint in Genotype-Guided Therapy arm 1738 were excluded from data analysis due Identified as CYP2C19 LOF noncarriers by TaqMan or no TaqMan results available. For 1 year endpoint in Conventional Therapy arm 1689 were excluded from data analysis due Identified as CYP2C19 LOF noncarriers by TaqMan or no TaqMan results available.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype-Guided Therapy</title>
            <description>Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year&#xD;
Ticagrelor: One 90 mg tablet twice per day by mouth for one year</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.</title>
          <description>Number of subjects who experienced major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis in subjects identified as CPY2C19 LOF carriers by TaqMan.</description>
          <population>For 1 year endpoint in Genotype-Guided Therapy arm 1738 were excluded from data analysis due Identified as CYP2C19 LOF noncarriers by TaqMan or no TaqMan results available. For 1 year endpoint in Conventional Therapy arm 1689 were excluded from data analysis due Identified as CYP2C19 LOF noncarriers by TaqMan or no TaqMan results available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="903"/>
                <count group_id="O2" value="946"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.</title>
        <description>Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding in subjects identified as CYP2C19 LOF carriers by TaqMan</description>
        <time_frame>1 year after percutaneous coronary intervention (PCI)</time_frame>
        <population>For 1 year endpoint in Genotype-Guided Therapy arm 1738 were excluded from data analysis due Identified as CYP2C19 LOF noncarriers by TaqMan or no TaqMan results available. For 1 year endpoint in Conventional Therapy arm 1689 were excluded from data analysis due Identified as CYP2C19 LOF noncarriers by TaqMan or no TaqMan results available.</population>
        <group_list>
          <group group_id="O1">
            <title>Genotype-Guided Therapy</title>
            <description>Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year&#xD;
Ticagrelor: One 90 mg tablet twice per day by mouth for one year</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.</title>
          <description>Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding in subjects identified as CYP2C19 LOF carriers by TaqMan</description>
          <population>For 1 year endpoint in Genotype-Guided Therapy arm 1738 were excluded from data analysis due Identified as CYP2C19 LOF noncarriers by TaqMan or no TaqMan results available. For 1 year endpoint in Conventional Therapy arm 1689 were excluded from data analysis due Identified as CYP2C19 LOF noncarriers by TaqMan or no TaqMan results available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="903"/>
                <count group_id="O2" value="946"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thrombolysis in Myocardial Infarction Major or Minor Bleeding</title>
        <description>Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding</description>
        <time_frame>Approximately 3 years after percutaneous coronary intervention (PCI)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype-Guided Therapy</title>
            <description>Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year&#xD;
Ticagrelor: One 90 mg tablet twice per day by mouth for one year</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombolysis in Myocardial Infarction Major or Minor Bleeding</title>
          <description>Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2641"/>
                <count group_id="O2" value="2635"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of the a Major Adverse Cardiovascular Event</title>
        <description>Number of subjects to experience a major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis.</description>
        <time_frame>Approximately 3 years after percutaneous coronary intervention (PCI)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genotype-Guided Therapy</title>
            <description>Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year&#xD;
Ticagrelor: One 90 mg tablet twice per day by mouth for one year</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy</title>
            <description>Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of the a Major Adverse Cardiovascular Event</title>
          <description>Number of subjects to experience a major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2641"/>
                <count group_id="O2" value="2635"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                    <measurement group_id="O2" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from baseline to end of study participation for a total of approximately one year on all participants.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Genotype-Guided Therapy</title>
          <description>Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year&#xD;
Ticagrelor: One 90 mg tablet twice per day by mouth for one year</description>
        </group>
        <group group_id="E2">
          <title>Conventional Therapy</title>
          <description>Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.&#xD;
Clopidogrel: One 75 mg tablet per day by mouth for one year</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="2641"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="2635"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2641"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2635"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2641"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2635"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Naveen L. Pereira</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-4441</phone>
      <email>Pereira.Naveen@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

